Methods: one hundred patients with ap lanned elective operation for benign or malignant gastrointestinal illness were randomized into two groups: group 1) oral supplementation for five days before and five days after surgery with 900 mL/day of aformula enriched with arginine, gamma-3-fatty acid and rna +liquid diet ad libitum on one and two postoperative day and then solid food (immunonutrition group; n=50) or group 2) no artificial nutrition before and after surgery,onone and two postoperativeday intravenous solution of 5% glucoseand electrolytes and then normal diet (conventional group; n=50).
INtroDuCtIoN
Major abdominal operations lead to post traumatic dysregulation of immune system, whichischaracterized by suppression of immune functions (1, 2). the increased susceptibility to infections results from a multitude of metabolic or immunologic imbalances accordingtotrauma, tissue ischemia and surgical injury,l ength of operation, loss of blood, associated illnesses and malnutrition (3). Mucosal lesions and increased intestinal permeability can provoke translocation of bacteria and endotoxins and initiate immune-inflammatory response andso thus have ahigh impact on the development of complications by infections (4-7). Enteral nutritionp rovides the intestinal mucosa with nutrients, and maintains the gut-associated lymphoid tissue (GALt), which may reduce bacterial translocation (8, 9) . In many early studiesperioperative administration of immune-enhancing formulas has shown to improve gut function and posi-tivelym odulate postsurgical immunosuppressive and inflammatory responses (10) (11) (12) (13) (14) .
Arginine, glutamine, omega-3-fatty acids and ribonucleic acid (rNA) areimmunonutrients, which can modulatet he immune system and improve host defence mechanisms after major surgery (15, 16) .
Argininep rotects againsti schemia/reperfusion injury,p romotes t-cell maturation and activation, and improves nitrogen balance (6, 9 ) . Glutamine servesasanimportant energy source forthe gut mucosa. Various immunologic cells and other rapidly dividing cells requireg lutamine for their metabolic processes (7, 8) . omega-3-fatty acids have ar ole in modulating theproduction of both lipid (eicosanoids) and protein (cytokines) mediators. they reduce systemic inflammation,m inimise hepatic ischemia injury and normalise vascular flow properties (6, 9) . Nucleotides improve protein synthesis, facilitate intestinal cell maturation, and have aregulatory role in the t-cell mediated immune response (6, 9, 17) .
The first clinical study of postoperativei mmunonutrition has been done by Daly in 1992 (18) . After that Senkel, Braga and Gianotti have studied post-, peri-and preoperative immunonutrition in gastrointestinal cancerpatients (19) (20) (21) (22) (23) . In most trials the results have been auspicious and especially preoperative immunonutrirition is advocated.
this study was conducted to determine if perioperative immunonutrition in elective gastrointestinal surgery patients(with malign or benign disease) could improve clinical outcomes.
MAtErIAL AND MEtHoDS
this was apilot prospective unblinded randomised study that was carried out at the Department of Surgery, Seinäjoki Central Hospital, Finland.
Patients with gastrointestinal tract illness who werecandidates for electivesurgery wereprospectively registered. Exclusion criteriaw erea ge younger than 16 years and pregnancy.A ll patients gave aw ritten informed consent according to the declaration of Helsinki once the details of the protocol weref ully explained. the Ethical Committee of Seinäjoki Central hospital approved the protocol. one hundred patients wererandomized by asealed envelopemethod into two groups:1)immunonutrition group (IG) (n =50) or 2) conventional group (CG) (n =50). Patients in the immunonutritiong roup werea sked to drink supplemented liquid diet (oral Impact ® ;Novartis Consumer Health, Bern, Switzerland) 300 ml three times daily for five consecutive days (= 15 doses) beforesurgery.The daily dose of 900ml oral Impact ® contains 12 garginine, 3gomega-3 fatty acids,1,2 grNA, and energy 900 kcal. Patients in the conventional group did not receive any supplementary diet. All patients wereadvised to adheretotheir normal diets before the operation. Hospital admission was scheduled for all patients one day beforesurgical procedure.
routine laboratory tests (haemoglobin, albumin, CrP, creatinine, glucose), weight,and presence of co morbidity factors wererecorded in all patients. No intestinal washout or enema was used. All patients received antibiotic prophylaxis. Patients wereadministered prior to the procedureiv cefuroxime (3 g) for those undergoing upper gastrointestinal tract operationa nd iv ceftriaxone (2 g) and metronidazole (1 g) for those undergoing lower tract operation. 40 patients in immunonutrition group and 44 patients in conventional group received single doses of antibiotics. If the durationofthe operation was longer than four hours or if the contamination risk was excessive, antibiotic prophylaxis was prolonged to four days (cefuroxime 1.5 g × 3/day or ceftriaxone1g× 1a nd metronidazole 0.5 g × 3/day). For deep vein thrombosisprophylaxis low weight heparin (dalteparin 2500 Iu) wasa dministerdt oa ll patiens. the operations wereperformed in total by six alimentary tract surgeons, but mainly by only two surgeons (60 of the 100 operations). All surgeons performed operations in both groups.
All patients hadg eneral anaesthesia and epidural analgesia (fentanyl +b upivakain). the epidural analgesia continued to two or threed ays postoperatively.t ype of operation, operation time, blood loss, blood transfusions, and intravenouss olutions werer egistered in all patients. All operations wereopen procedures.
Postoperatively the patients in immunonutrition group wereg iven liquid diet on day one and two and solid diet after that (+ oral Impact ® 900 ml/day first five days). They weregiven an intravenous solution of 5% glucose and elec-trolytes1 -2 Lo nfi rst days in case if they could note at enough (over 1L). Jejunal infusions weren ot used in any patients. In the conventional treatment group the patients weregiven an intravenous solution of 5% glucose and electrolytes 3L/day,and they did not receive any alimentation per os until the day three.
General wellbeing, nausea, abdominal bloating, flatulence and diarrhoea weree valuated by using the visual analogue scale (VAS). the scale runs from 0( 0=comfortable, no symptoms) to 100 (100 = uncomfortable, bad symptoms).Patients in both groups filled in aquestionnaireone day beforeand six days after the operation.
the following blood test battery was performed on all patients on the day prior to the surgery and on day two and six postoperatively: haemoglobin, albumin, CrP, creatinine and glucose. Blood culturew as performed and analysed if patient had fever over 38 degrees Celsius. urine culture was checked if therew ereu nclear infectious symptoms, and chest radiograph was taken in case of respiratory symptoms. All complications , their treatments and the day of the hospital discharge werer egistered. An outpatient checkup of all patients was carried out approximatelyfive weeks after operation to follow up for possible complications.
StAtIStICS
In the recent studies, the mean infectious complication rate has been about 30 %after major gastrointestinal surgery.Apower calculation revealed that to detect statistically significant infection rate reduction from 30 %to20%between two treatment arms, 310 patients in each arms arer equired. that means multicentry study and morec onfounding factors. our study was done as ap ilot study in an average-sized central hospital. Descriptive results arer eported as number of patients, mean +/-SD, and median and range in case of not normally distributed data. Independent-Samples t-test and two-Independent-Samples test (for not normallyd istributed data)w ere used to comparevariables among the groups. Fisher exact test was used to comparediscrete variables. All pvalues aretwo sided, and significance was set at p <0 .05. the SPSS package version 11.5 for Windows was used for the statistical analysis. rESuLtS the groups werecomparable for baseline and surgical characteristics. Low preoperative serum albumin (< 35 g/l) value was found in 22% of the patients and one patient had very low level (< 28 g/L). Mean BMI was 27 (range 16-45) kg/m 2 (table 1). 60% of the patients had cancer (table 2) .
Beforesurgery 45 (90%) patients in the immunonutrition group drank 12-15 dosesoforal Impact ® ,and remaining five patients drank 5-11d oses. After the operation 15 (30%) patientsreached the target of 12-15 doses of oral Impact ® during the first five postoperative days, whereas the others drank mean eight doses (0-11d oses). twop atients could not eat anything in first two postoperative days. All other patients in the immunonutrition group wereable to take mean 1800 ml (range5 00-3500 ml) liquid nutrition per aday.Inthe immunonutrition group 80% of the patients wereable to eat normally on day three.
Patients in the immunonutritiong roup had more abdominal bloating (IG VA Smedian (range) 21 (0-80) vs. CG 4(0-73), p=0.015 on day two; IG 18 (0-80) vs. CG 6.5 (0-72), p=0.022 on day six) and flatulence(IG 19 (0-81) vs. CG 3( 0-73), p=0.042 on day two) , whereas no significant difference between the groups was found in postoperative nausea, diarrhea or in general wellbeing. The mean time to the firstflatus or defecation was 2.8 days after surgery in the immunonutrition group and 3.5 days in the conventional group, respectively (p =0.062). In laboratory tests CrP rates werelower in the conventional group preoperatively (IG median (range) 10 (2-53) vs. CG 10 (1-35),p=0.026) and also postoperatively (on day two IG 154 (48-319) vs. CG 145 (33-226), p=0.043); on day six 46 (10-229) vs. 29 (6-126), p=0.017); at the checkup 10 (2-36) vs.1 0( 1-20), p=0.024). In the other laboratory tests no significant differences between the groups was observed. the total number of postoperative complications was 26, of which 14 (28%) wereinthe immunonutrition group and 12 (24%) in the conventional group. therew eren ine (18%) infectious complications and five other complications in the immunonutrition group, and nine (18%) infectious and three other complications in the conventional group, respectively (p =ns) (table 3) . Therew as no significant difference in any complication rates between patients with malignant or benign disease. No significant difference between the surgeons in complication rates was found. Four patients had reoperations, of which three wereoperated for anastomotic leaks and abdominal infections and one for intestinal obstruction. other complications weret reated conservatively by using antibiotics and nasogastric tube. the mean hospital stay was ten days in the immunonutrition group and nine days in the conventional group. three patients died. one in the immunonutrition group died for anastomotic leak and cardiac failure, and one in the conventional group for anastomotic leak and respiratory failureand the second for abdominal infection and cardiac failure. 
DISCuSSIoN
Nutritional support becameinitially popular through the observation that malnutrition is associated with ap oor clinical outcome. Malignanciesa nd surgical stress can influence negatively patient's immune system and other defencem echanisms. Infections area big problem after majora bdominal surgical procedures, contributing to increased morbidity, mortality and healthcarecosts. During the last 15 years, enteral immunonutrition has been shown to improve outcome in major abdominalcancer surgery (18) (19) (20) (21) (22) .
In the first studies of immunonutrition, the supplement was given only after operation. In 1992 Daly et al. published astudyofpostoperative immunonutrition in the patients undergoing majoro peration for the upper gastrointestinal malignancies (18) . they found asignificant decrease in the infectious complication rates. In 1997 Hesline ta l. compared early postoperative immunonutritionw ith no nutritional support in the patients with upper gastrointestinal malignancies (23) . In this study postoperative immunonutrition was not beneficial. In 2002 Braga, Gianotti et al. found out that perioperative immunotherapy resulted the best outcome in 150 malnourished (weight loss >10% over 6mo) surgical gastrointestinal cancer patients (24) , while in 305 well-nourished preoperative administrationofimmunonutrition was as effective as the perioperative immunonutrition (25) .
Meta-analysisb yH eyes (11t rials, 1009 patients) and Beale (12 trials, 1482 patients) in 1999, Heyland (22 trials, 2419 patients) in 2001, and Sacks (7 trials, 1058 patients) in 2003 showed that immunonutrition was associated with significantly fewer infectious complications and ashorter length of hospital stay in elective surgical patients (26) (27) (28) . therewas no effect on mortality.the latest review by Sacks reveals that especially preoperative immunonutrition is beneficial, not postoperative (29) .
In review from McCowen et al (2003) it was suggested that the formulao fi mmunonutritions hould containa rginine >12g /L, duration of treatment should be >t hree days (preferably 5-10 days) and feeding goals should approach 25 kcal/kg, and >800 ml/d (30) . Current commercial oral immunonutrition formulas do not include significant amount of glutamine. the most popular supplement formulaswhich have been studied in this context areI mpact® and Immun-Aid ® (B Braun, Irvine, CA).
the aim of our study was to investigate how oral immunonutrition effects the recovery of non-selected gastrointestinal surgical patients. the postoperative treatment of control group patients followed the formula which is still "gold standard" in many Finnish hospitals, n.p.o. two to three days after operation. Most patients in our study werewell nourished and 40% of the patients had benign disease. Majority (84%) of the operations herewereresections of lower gastrointestinal tract. other trials of perioperative immunonutritionh ave been carried out by giving the supplement diet via jejunal infusion. We wanted to minimize the use of tubes because they may disturb mobilization and the overall recovery of patients. our total and infectious complications rates were well comparable with previous studies in immunonutrition group, and in conventional group the rates werelittle lower than in the other studies (12, 20, 23, 24) . therew as no difference in any complications rates between the groups. the only distinct difference was on CrP, which was greater in the immunonutrition group beforeand weeks' time after operation. It may be as ign of stronger inflammation reaction caused by immunonutrition. However,t he impact was not specific enough.
our study has some limitations. the number of patients in the groups did not guarantee statistical power.Inaclinical study like this, it is impossible to determinepatients`diet at homebeforecomingto the hospital. It is also difficult to arrange standardd iet after different kinds of operations. Local menu and meal times werep reserved in order to analyse the role of immunonutrition and normal eating versus old system with glucose infusions down to third postoperative day.P ostoperatively only 30% of the patientsc ould drink over 11 doses of oral Impact ® , because the beverageisquite filling and few patients areh ungry after abdominal operations on the first postoperative days. However,almost all the patients could drink over 12 doses preoperatively receiving immunonutrientsa tap hase wheret hey werem ost beneficial (23) (24) (25) 29) .
It is known that the risk for complications is greater in the upper gastrointestinal cancer surgery than in the colon operations (31) . the average good nutritional status,great proportion of benign diseases and lower abdominal operations in our study might have had some impact on the result that immunonutrition was not beneficial. On the other hand, immunonutrition may cause some unpleasant side effects,like abdominal bloating, which can prohibit normal eating. Early oral feeding per se has been generally well tolerated (32) . While the costs of immunonutrients are quite high and the benefit of this prophylactic therapy is questionable, our conclusion is that we do not suggest immunonutrition routinely to all patients with major gastrointestinal surgery.However,studies with large number of patients areneeded before final recommendations. In futurestudies,itmay be better to focus on the preoperative immunonutrition in cases of major upper gastrointestinal surgery. 
